GNLX (Genelux Corporation) stock: $1.98, $89.4M market cap, $16.7M cash, $72.7M EV, $121.9M fully diluted market cap. Next expected readout: Dec-26. Lead program: olvimulogene nanivacirepvec (Platinum-resistant Ovarian Cancer), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
Our clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Importantly, our oncolytic immunotherapy product candidates are “off-the-shelf” personalized immunotherapies.
Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Metastatic Non-squamous Non Small Cell Lung Cancer
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Lead product candidate; proprietary modified vaccinia virus oncolytic immunotherapy. Phase 3 On Prime/GOG-3076 registration trial ongoing; Phase 1b/2 VIRO-15 in PRROC (translational/clinical findings published June 2026). VIRO-25 Phase 2 in NSCLC run by Newsoara. Extensive engineered oncolytic VACV library (CHOICE platform) with no distinct additional candidate named.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.